Not yet recruiting

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

By April 24, 2017 No Comments


Pleural Mesothelioma Malignant Advanced

Estimated Enrollment: 142

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: ETOP 9-15|2016-002062-31|3475-594

Study First Received: December 9, 2016

Last Updated: December 9, 2016

Estimated Primary Completion Date: November 2020


Primary Outcome Measures:

Progression Free Survival (PFS) in patients with advanced pre-treated malignant mesothelioma.|Objective response.|Overall survival.|Time to treatment failure.|Toxicity/adverse events.|Investigator assessed PFS

Sponsors and Collaborators:

European Thoracic Oncology Platform|Merck Sharp & Dohme Corp.|Frontier Science Foundation, Hellas

Website Link:

Leave a Reply

Call Now